Press Releases

Press Releases

Date Title and Summary Additional Formats
Jun 23, 2020 Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer
- Pete Curry has been Promoted to Vice President of Sales - Maria Pandolfo has been Promoted to Vice President of Patient Services CORAL GABLES, Fla. , June 23, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on
Jun 01, 2020 Catalyst Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
CORAL GABLES, Fla. , June 01, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
May 11, 2020 Catalyst Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update
Firdapse® Q1 2020 Net Revenues of $29.1 Million First Quarter 2020 GAAP Net Income of $10.4 Million Catalyst Withdraws Previous 2020 Revenue Guidance Due to COVID-19 Uncertainties Catalyst to Host Quarterly Conference Call at 8:30 AM ET Tomorrow CORAL GABLES, Fla.
May 04, 2020 Catalyst Pharmaceuticals to Hold First Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 12th, 2020
CORAL GABLES, Fla. , May 04, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Apr 08, 2020 Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities
Safety of personnel, patients and healthcare providers remains our top priority   Drug supply remains well-stocked with patients having access to uninterrupted supply of Firdapse® (amifampridine) 10mg   Catalyst partners with First Responders Children’s Foundation to support COVID-19 EMERGENCY
Mar 16, 2020 Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
-Firdapse ® Q4 Net Revenues of $30 Million , FY 19 Net Revenues of $102 Million -GAAP Net Income of $32 Million for Fiscal Year 2019 -Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020 -Firdapse Supply Chain in Solid Position-Significant Safety Stock
Mar 10, 2020 Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020
CORAL GABLES, Fla. , March 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Feb 27, 2020 Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020
CORAL GABLES, Fla. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Feb 26, 2020 Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference
CORAL GABLES, Fla. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Feb 06, 2020 Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference
CORAL GABLES, Fla. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological

Displaying 1 - 10 of 12